{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:53:18Z","timestamp":1791377598360,"version":"4.3.2"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,9,19]]},"DOI":"10.18632\/oncotarget.18215","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T05:10:37Z","timestamp":1495775437000},"page":"69219-69236","source":"Crossref","is-referenced-by-count":162,"title":["Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt\u2019s lymphoma anti-tumor activity"],"prefix":"10.18632","volume":"8","author":[{"given":"Nicola J.","family":"Curtis","sequence":"first","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Mooney","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Hopcroft","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippos","family":"Michopoulos","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Whalley","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Zhong","sequence":"additional","affiliation":[{"name":"MedImmune, One MedImmune Way, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Murray","sequence":"additional","affiliation":[{"name":"iMED DSM, AstraZeneca, Cambridge, UK"},{"name":"C4X Discovery, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Logie","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Revill","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate F.","family":"Byth","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Gatehouse Park, Waltham, Massachusetts, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda D.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"iMED DSM, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike A.","family":"Firth","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Green","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Smith","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Critchlow","sequence":"additional","affiliation":[{"name":"iMED Oncology, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Dang","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Thompson","year":"2009","journal-title":"Science"},{"key":"3","first-page":"281","article-title":"The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation","volume":"343 Pt 2","author":"Price","year":"1999","journal-title":"Biochem J"},{"key":"4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mam.2012.05.003","article-title":"The SLC16 gene family - structure, role and regulation in health and disease","volume":"34","author":"Halestrap","year":"2013","journal-title":"Mol Aspects Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2009.06.018","article-title":"The prognostic value of CD147\/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer","volume":"45","author":"Baltazar","year":"2009","journal-title":"Eur J Cancer"},{"key":"6","article-title":"Prognostic significance of lactate\/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder","volume":"84","author":"Kim","year":"2014","journal-title":"Urology"},{"key":"7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10863-012-9408-5","article-title":"Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs)","volume":"44","author":"Baltazar","year":"2012","journal-title":"J Bioenerg Biomembr"},{"key":"8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.humpath.2014.09.013","article-title":"Expression of lactate\/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses","volume":"46","author":"Kim","year":"2015","journal-title":"Hum Pathol"},{"key":"9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00428-012-1344-6","article-title":"Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma","volume":"462","author":"Nabeshima","year":"2013","journal-title":"Virchows Arch"},{"key":"10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbrc.2008.06.122","article-title":"Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism","volume":"374","author":"Nishizawa","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"11","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1227\/01.NEU.0000143034.62913.59","article-title":"Silencing of monocarboxylate transporterssmall interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: anstudy","volume":"55","author":"Sloan","year":"2004","journal-title":"Neurosurgery"},{"key":"12","first-page":"3930","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","volume":"118","author":"Wahl","year":"2008","journal-title":"J Clin Invest"},{"key":"13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/0008-5472.CAN-05-3260","article-title":"Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma","volume":"66","author":"Sivridis","year":"2006","journal-title":"Cancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1073\/pnas.97.7.3260","article-title":"Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion","volume":"97","author":"Golub","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/mp800116f","article-title":"C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells","volume":"6","author":"Han","year":"2009","journal-title":"Mol Pharm"},{"key":"16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","article-title":"Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis","volume":"74","author":"Rounbehler","year":"2014","journal-title":"Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/onc.2015.360","article-title":"Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters","volume":"35","author":"Qing","year":"2016","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Gascoyne","year":"2009","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Jack","year":"2010","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/1097-0142(197902)43:2<417::AID-CNCR2820430203>3.0.CO;2-I","article-title":"Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study","volume":"43","author":"Coltman","year":"1979","journal-title":"Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Gisselbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Ferm\u00e9","year":"2010","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOPCHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Horning","year":"2006","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"122","author":"Campo","year":"2013","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1042\/bj2690827","article-title":"Substrate and inhibitor specificity of monocarboxylate transport into heart cells and erythrocytes. Further evidence for the existence of two distinct carriers","volume":"269","author":"Levi","year":"1990","journal-title":"Biochem J"},{"key":"26","doi-asserted-by":"crossref","first-page":"20011","DOI":"10.1074\/jbc.M109.014217","article-title":"Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle","volume":"284","author":"Halestrap","year":"2009","journal-title":"J Biol Chem"},{"key":"27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/bj1480097","article-title":"The specificity and metabolic implications of the inhibition of pyruvate transport in isolated mitochondria and intact tissue preparations by alpha-Cyano-4-hydroxycinnamate and related compounds","volume":"148","author":"Denton","year":"1975","journal-title":"Biochem J"},{"key":"28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1042\/bj1480085","article-title":"The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors","volume":"148","author":"Halestrap","year":"1975","journal-title":"Biochem J"},{"key":"29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/BJ20091515","article-title":"AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10","volume":"425","author":"Halestrap","year":"2010","journal-title":"Biochem J"},{"key":"30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nchembio744","article-title":"Monocarboxylate transporter MCT1 is a target for immunosuppression","volume":"1","author":"Holness","year":"2005","journal-title":"Nat Chem Biol"},{"key":"31","first-page":"2260","article-title":"Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds","volume":"16","author":"Kingston","journal-title":"Bioorg Med Chem Lett"},{"key":"32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1042\/BJ20151120","article-title":"The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters","volume":"473","author":"Halestrap","year":"2016","journal-title":"Biochem. J"},{"key":"33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-14-2260","article-title":"Genetic disruption of lactate\/H+ symporters (MCTs) and their subunit CD147\/BASIGIN sensitizes glycolytic tumor cells to phenformin","volume":"75","author":"Pouyssegur","year":"2015","journal-title":"Cancer Res"},{"key":"34","first-page":"2891","article-title":"Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells","volume":"36","author":"Avila","year":"1976","journal-title":"Cancer Res"},{"key":"35","first-page":"323","article-title":"Lethal effect of adriamycin on the division cycle of HeLa cells","volume":"32","author":"Kim","year":"1972","journal-title":"Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2015.01.009","article-title":"MYC alterations in diffuse large B-cell lymphomas","volume":"52","author":"Campo","year":"2015","journal-title":"Semin Hematol"},{"key":"37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coph.2014.07.001","article-title":"Emerging approaches to target tumor metabolism","volume":"17","author":"Critchlow","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"38","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/1078-0432.CCR-13-2270","article-title":"Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer","volume":"20","author":"Dive","year":"2014","journal-title":"Clin Cancer Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.1073\/pnas.1106123108","article-title":"CD147 subunit of lactate\/H+ symporters MCT1 and hypoxia-inducbible MCT4 is critical for energetics and growth of glycolytic tumours","volume":"108","author":"Pouyss\u00e9gur","year":"2011","journal-title":"Proc. Natl. Acad. Sci USA"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Tewey, Rowe, Yang, Halligan, Liu. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984; 226:466\u20138.","DOI":"10.1126\/science.6093249"},{"key":"41","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0006-2952(96)00050-0","article-title":"Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin","volume":"51","author":"Gewirtz","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.14348\/molcells.2014.0210","article-title":"The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells","volume":"37","author":"Jiang","year":"2014","journal-title":"Mol Cells"},{"key":"43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/BJ20040776","article-title":"PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis","volume":"386","author":"Oliver","year":"2005","journal-title":"Biochem J"},{"key":"44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/nbm.3240","article-title":"Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin","volume":"28","author":"Glickson","year":"2015","journal-title":"NMR in Biomedicine"},{"key":"45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Hassa","year":"2015","journal-title":"Mol Cancer"},{"key":"46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolismTCA cycling for proliferation and survival in B cells","volume":"15","author":"Slebos","year":"2012","journal-title":"Cell Metab"},{"key":"47","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V122.21.4226.4226","article-title":"Antitumor Activity Of The Glutaminase Inhibitor CB-839 In Hematological Malignances","volume":"122","author":"Bennett","year":"2013","journal-title":"Blood"},{"key":"48","article-title":"Selective inhibition of glutaminse by bis-thiadiazoles","author":"Newcomb","year":"2002","journal-title":"U.S. Pat. 6,451,828B1"},{"key":"49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chroma.2014.05.019","article-title":"Targeted profiling of polar intracellular metabolites using ion-pair-high performance liquid chromatography and -ultra high performance liquid chromatography coupled to tandem mass spectrometry: applications to serum, urine and tissue extracts","volume":"1349","author":"Critchlow","year":"2014","journal-title":"J Chromatogr A"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T15:40:59Z","timestamp":1596728459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":49,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,9,19]]}},"alternative-id":["18215","29050199"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18215","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}